Pine River Capital Management’s Cellectar Biosciences CLRB Stock Holding History

Pine River Capital Management’s Portfolio CLRB Stock Details CLRB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-17	Closed	–	–	675
2015 Q4	$0	Hold	17	–	–	﹤0.01%	680
2015 Q3	$0	Hold	17	–	–	﹤0.01%	645
2015 Q2	$0	Buy	+17	New	+$1.49M	﹤0.01%	693

Other funds holding CLRB

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Wealthspire Advisors (Maryland) Potomac, Maryland $2.84B AUM 10.91% 1-Year Est. Return

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Northwestern Mutual Wealth Management

Northwestern Mutual Wealth Management Milwaukee, Wisconsin $162B AUM 16.35% 1-Year Est. Return

Pine River Capital Management's CLRB Position: Q1 2016 in Review

Pine River Capital Management sold out of Cellectar Biosciences (CLRB) in Q1 2016, closing a stake of 17 shares.

Pine River Capital Management first reported a position in CLRB in Q2 2015 and held it in 3 quarters. The position peaked at $0 in Q4 2015. 4 funds tracked by Wall St. Rank hold CLRB as of Q1 2016.

Pine River Capital Management reported no remaining Cellectar Biosciences position as of Q1 2016 after selling out during the quarter.
Pine River Capital Management sold 17 Cellectar Biosciences shares in Q1 2016.
Pine River Capital Management first reported a position in Cellectar Biosciences in Q2 2015 and held it in 3 quarters.
Pine River Capital Management's Cellectar Biosciences position peaked at $0 in Q4 2015.
4 funds tracked by Wall St. Rank held Cellectar Biosciences as of Q1 2016.

Based on Pine River Capital Management's 13F filing for Q1 2016, filed 16 May 2016.